BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 237 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $879 | -23.6% | 172,961 | -10.0% | 0.01% | -12.5% |
| Q4 2023 | $1,151 | -78.3% | 192,202 | -74.4% | 0.01% | -84.3% |
| Q3 2023 | $5,310 | -37.8% | 750,053 | -38.1% | 0.05% | -26.1% |
| Q2 2023 | $8,536 | -16.2% | 1,212,547 | -0.7% | 0.07% | -17.9% |
| Q1 2023 | $10,189 | +3959.4% | 1,221,681 | +5493.3% | 0.08% | +2000.0% |
| Q4 2022 | $251 | -100.0% | 21,842 | -96.9% | 0.00% | -96.6% |
| Q3 2022 | $8,937,000 | +19.2% | 709,285 | +0.1% | 0.12% | +27.2% |
| Q2 2022 | $7,500,000 | +348.3% | 708,919 | +486.7% | 0.09% | +441.2% |
| Q4 2021 | $1,673,000 | +175.2% | 120,827 | +185.7% | 0.02% | +112.5% |
| Q3 2021 | $608,000 | -68.4% | 42,295 | -65.2% | 0.01% | -61.9% |
| Q2 2021 | $1,923,000 | +1024.6% | 121,603 | +238.1% | 0.02% | +425.0% |
| Q2 2020 | $171,000 | – | 35,969 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |